Dobroslav Hájek
Masaryk University
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Dobroslav Hájek.
Ophthalmologica | 2001
Kateřina Kaňková; Jan Mužík; Jana Karásková; Michal Beránek; Dobroslav Hájek; Vladimír Znojil; Eva Vlková; Jiří Vácha
The object of the study was to investigate the share of the polymorphisms I/D ACE, endothelin 1 4127G/A and TNF-β NcoI in the susceptibility to proliferative diabetic retinopathy (PDR) in non-insulin-dependent diabetes mellitus (NIDDM). Genotypes were detected by polymerase chain reactions and determined in a set of 246 Caucasian NIDDM subjects with defined PDR status. The relevance of genotypes and clinical characteristics to the PDR occurrence was tested using multiple linear regression models and discrimination analysis. The best predictive value for PDR was given by a combination of two parameters – NIDDM duration and the TNF-β genotype (p < 1·10–6 and p = 1·10–2, respectively) with a correct retrograde prediction of 82.6%. A comparison of the TNF-β NcoI allele frequencies revealed no difference between NIDDM and nondiabetic subjects (n = 176), but a statistically significant difference was found between PDR and non-PDR NIDDM subjects (after a correction for the number of comparisons p = 0.03), allele β2 being associated with PDR. Our results identified the allele variant TNF-β2 being associated with PDR in NIDDM. Diabetes duration and the TNF-β NcoI genotype were proven to significantly predict PDR occurrence. The TNF-β2 allele could be regarded as a separate genetic risk factor that increases the relative incidence of PDR in patients with NIDDM.
Retina-the Journal of Retinal and Vitreous Diseases | 2002
Kateřina Kaňková; Michal Beránek; Dobroslav Hájek; Eva Vlková
Pilot study perfromed on 531 Caucasian subjects proved that intron polymorphisms 1704G/T, 2184A/G and 2245G/A in the gene encoding receptor of advanced glycation end products (RAGE) are not associated with proliferative diabetic retinopathy in NIDDM.
Medical Hypotheses | 2003
Dobroslav Hájek; Miroslav Tomíška; Eva Krahulcová; Miloslav Druckmüller; Michaela Florianova; Lydie IzakovičováHollá; Jiri Vacha
Angiotensin-I converting enzyme (ACE) is involved not only in intracellular volume regulation but also in proliferation control. Since both ACE gene polymorphism (I/D ACE) and ABO blood group determine ACE level in peripheral blood and probably also in bone marrow, the hypothesis to the interindividual differences in survival of leukemic patients was suggested. The data of 25 patients of both sexes with acute myelogenous (AML), acute lymphatic (ALL), chronic myelogenous (CML) and chronic lymphatic (CLL) leukemia treated by conventional were used for the study. The overall survival (SUR) was estimated as the time from the date of diagnosis to the date of death. The difference between patients individual SUR (iSUR) and median SUR according to the type of leukemia (mSUR) was calculated. This difference (iSUR-mSUR) varied with I/D ACE genotype (p<0.02) but neither with diagnosis nor with ABO blood group. The regression model for iSUR calculation, from mSUR and I/D ACE genotype, has been suggested.
Stem Cells | 1999
Dobroslav Hájek; Hana Matějovská Kubešová; Rostislav Vyzula; Jiri Mayer; Miloslav Druckmueller; Miroslav Tomíška; Anna Vasku
The local renin‐angiotensin system (RAS) in bone marrow is probably involved in the control of hematopoiesis. Earlier observations suggest the relationship between the frequency of sodium and potassium concentration changes in urine and bone marrow recovery after chemotherapy. The purpose of this study was to prove the relationship between sodium and potassium excretion changes in urine and granulocyte counts in peripheral blood after autologous bone marrow and peripheral blood stem cell transplantation.
American Journal of Medical Genetics | 2002
Michal Beránek; Kater̆ina Kan̆ková; Petr Benes̆; Lydie Izakovic̆ová-Hollá; Vladimír Znojil; Dobroslav Hájek; Eva Vlková; Jir̆í Vácha
Kidney International | 1998
Anna Vašků; Miroslav Souček; Vladimír Znojil; Ivan Řiháček; Svatava Tschöplová; Lenka Střelcová; Karel Cídl; Michaela Blažková; Dobroslav Hájek; Lydie Izakovičová Hollá; Jiří Vácha
Diabetes Care | 1999
Kateřina Kaňková; Anna Vašků; Dobroslav Hájek; Jiří Záhejský; Vladimír Vašků
Physiological Research | 1999
Anna Vašků; Miroslav Souček; Dobroslav Hájek; Lydie Izakovičová Hollá; Vladimír Znojil; Jiří Vácha
Archive | 2003
Kateřina Kaňková; Dobroslav Hájek; Marcel Horký; Lydie IzakovičováHollá; Michal Jurajda; Vladimír Kotala; Jiří Vácha; Anna Vašků; Vladimír Znojil
Medical Hypotheses | 2005
Dobroslav Hájek; Kolár P; Philip K. Maini; Pavel Starha